Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Símbolo de cotizaciónSCNX
Nombre de la empresaScienture Holdings Inc
Fecha de salida a bolsaFeb 18, 2020
Director ejecutivoHariharan (Shankar)
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 18
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónSCNX
Fecha de salida a bolsaFeb 18, 2020
Director ejecutivoHariharan (Shankar)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos